SCHEMBL8717984

SCHEMBL8717984

CCCCc1c(N2CCC(NC(=O)c3ccccc3Oc3ccccc3)CC2)ccc2c1C(C(=O)NCC(F)(F)F)c1ccccc1-2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 2/20 0.42
▸ HPGDS O60760 1/20 0.36
▸ HTR7 P34969 3/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ KDM5A P29375 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ MTTP P55157 2/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ ADRA2A P08913 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ DRD1 P21728 1/20 0.35
▸ TBXA2R P21731 1/20 0.35
▸ PTGS1 P23219 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35
▸ ADRA1A P35348 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8712539 0.98 CCR3 (0.42) CCR3HPGDSHTR7HTR1ADRD2
SCHEMBL8665519 0.96 CCR3 (0.40) CCR3HPGDSHTR7HTR1ADRD2
SCHEMBL8665528 0.94 CCR3 (0.40) CCR3HPGDSHTR7HTR1ADRD2
SCHEMBL8653115 0.89 CCR3 (0.43) CCR3HPGDSHTR7HTR1ADRD2
SCHEMBL8713182 0.88 CKS1B (0.38) HTR1ADRD2DRD3POLB
SCHEMBL8482397 0.88 CCR3 (0.35) CCR3KDM5AKDM4EMTTPOPRM1
SCHEMBL8668022 0.88 FPR1 (0.36) CCR3NPSR1L3MBTL1TSHR
SCHEMBL8648478 0.87 CCNE1 (0.37) CCR3MEN1KMT2AMTTPCHRM2
SCHEMBL8654366 0.86 KMT2A (0.40) DRD2MEN1KMT2AADRA2ASLC6A2
SCHEMBL8651966 0.85 SLC6A12 (0.36) DRD2MTTPCHRM2ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5739135-A PREVENTING OR TREATING ATHEROSCLEROSIS, PANCREATITIS SECONDARY TO HYPERTRIGLYCERIDEMIA, HYPERGLYCEMIA, OBESITY BRISTOL-MYERS SQUIBB COMPANY (US) 1998-04-14 — — US disclosed
Send feedback